8-K
filed June 8, 2026, 4:01 PM ET
ticker STRO
CIK 0001382101
other
confidence high
sentiment neutral
materiality 0.15
Sutro Biopharma stockholders elect three Class II directors and ratify auditor at 2026 annual meeting
SUTRO BIOPHARMA, INC.
- Directors Jane Chung (11.4M for), Connie Matsui (9.7M for), James Panek (9.7M for) elected to three-year terms.
- Ratification of Ernst & Young as auditor for 2026 passed with 13.9M for, 501 against.
- Non-binding advisory vote on named executive officer compensation approved with 11.3M for.
- Broker non-votes totaled 2,540,863 on director election and say-on-pay items.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
SUTRO BIOPHARMA, INC. shareholders approved Election of three Class II directors at the 2026-06-05 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
On June 5, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”), and the following proposals were adopted: 1. Election of three Class II directors
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
SUTRO BIOPHARMA, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-05 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
2. Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Shares For Shares Against Shares Abstaining 13,893,289 501 5,883
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
SUTRO BIOPHARMA, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting at the 2026-06-05 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-05
Exact text from the filing
3. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting: Shares For Shares Against Shares Abstaining Broker Non-Votes 11,329,946 22,412 6,452 2,540,863
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.